Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 3,288 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 3,288 shares of Castle Biosciences stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $32.67, for a total transaction of $107,418.96. Following the completion of the sale, the insider owned 35,565 shares in the company, valued at approximately $1,161,908.55. This trade represents a 8.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Performance

CSTL stock opened at $34.50 on Friday. The firm has a 50-day simple moving average of $34.33 and a 200-day simple moving average of $28.37. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.28 and a quick ratio of 5.12. Castle Biosciences, Inc. has a 52 week low of $17.72 and a 52 week high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.22. Castle Biosciences had a negative net margin of 6.10% and a negative return on equity of 4.89%. The firm had revenue of $101.95 million for the quarter, compared to analyst estimates of $92.76 million. On average, analysts predict that Castle Biosciences, Inc. will post -0.83 EPS for the current year.

Institutional Trading of Castle Biosciences

Several large investors have recently bought and sold shares of the business. Advisors Capital Management LLC acquired a new position in shares of Castle Biosciences during the 2nd quarter worth approximately $5,681,000. BlackRock Inc. purchased a new stake in shares of Castle Biosciences in the second quarter valued at about $78,513,000. Bank of New York Mellon Corp acquired a new stake in Castle Biosciences during the second quarter worth about $2,338,000. Empowered Funds LLC acquired a new stake in Castle Biosciences during the second quarter worth about $3,395,000. Finally, Quantinno Capital Management LP increased its position in Castle Biosciences by 387.3% during the first quarter. Quantinno Capital Management LP now owns 45,476 shares of the company’s stock worth $1,116,000 after purchasing an additional 36,144 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on CSTL. Mizuho began coverage on Castle Biosciences in a research report on Thursday, October 29th. They issued an “outperform” rating and a $60.00 target price on the stock. Wall Street Zen upgraded Castle Biosciences from a “hold” rating to a “buy” rating in a research report on Sunday, November 1st. BTIG Research boosted their price target on Castle Biosciences from $44.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday. Robert W. Baird increased their price objective on Castle Biosciences from $39.00 to $41.00 and gave the company an “outperform” rating in a research note on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Castle Biosciences in a report on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Castle Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $46.50.

Castle Biosciences Company Profile

Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company’s portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett’s esophagus.